Capricor Therapeutics reported -6031530 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Bioline Rx BLRX:US -6079000 519K
Bluebird Bio BLUE:US $ -120346000 138.95M
Capricor Therapeutics CAPR:US -6031530 2.85M
Cytokinetics CYTK:US $ -77857000 58.95M
Cytori Therapeutics CYTX:US $ -3926000 285K
Geron GERN:US $ -28675000 2.31M
Johnson & Johnson JNJ:US $ 7540M 1623M
Newlink Genetics NLNK:US -7731000 1.16M
Prothena PRTA:US -37944000 4.85M
Ptc Therapeutics PTCT:US $ -86522000 1.79M
Sarepta Therapeutics SRPT:US $ -86881000 18.93M
Vascular Biogenics VBLT:US -10564000 1.45M
Vital Therapies VTL:US $ -21435000 286K